Product Description
Mechanisms of Action: ADORA3 Stimulant
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OncoVista
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Leukemia|Oncology Solid Tumor Unspecified
Phase 1: Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2400088428 |
ChiCTR2400088428 | N/A |
Not yet recruiting |
Asthenia |
2027-02-28 |
|||
ChiCTR2300075042 |
ChiCTR2300075042 | N/A |
Recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2025-06-01 |
2023-08-24 |
Treatments |
|
ChiCTR2500112208 |
ChiCTR2500112208 | N/A |
/Completed |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2024-11-30 |
|||
ChiCTR-INR-17014074 |
ChiCTR-INR-17014074 | N/A |
Not yet recruiting |
Depressive Disorder, Major |
2019-12-31 |
|||
NCT00003005 |
CDR0000065572 | P1 |
Completed |
Leukemia |
2001-03-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
NCT07002502 |
LK2025016 | P2 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2026-05-26 |
2025-06-04 |
Primary Endpoints|Treatments |
|
NCT00709215 |
OV06-001 | P2 |
Unknown status |
Leukemia |
2010-12-01 |
2019-03-18 |